New combo therapy targets advanced lung cancer in Mid-Stage trial
NCT ID NCT04736823
First seen Mar 14, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This phase II study tests a new drug called AK112 (a bispecific antibody that targets PD1 and VEGF) combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (stage IIIB/C or IV). The goal is to see if the combination shrinks tumors and how safe it is. Participants must be 18-75 years old and in fairly good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen University Cancer Center
Guanzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.